This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThermoGenesis Reports Second Quarter Fiscal 2013 Results

Net Loss Reduced by 56 Percent Year-Over-Year

Positive Clinical Study Results Published

RANCHO CORDOVA, Calif., Feb. 12, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of cell therapies, today reported results for the second quarter and first six months of fiscal 2013.

For the quarter ended December 31, 2012, revenues of $4.8 million were comparable to revenues in the second quarter a year ago and up substantially from revenues of $4.1 million in the prior quarter. Revenues for the second quarter of 2013 versus the same period a year ago reflect increased sales of the Company's BioArchive ® System devices, offset by declines in BioArchive disposable revenues, as well as CryoSeal product sales—which the Company divested in the first quarter of fiscal 2013.

ThermoGenesis reported a net loss of $563,000, or $0.03 per share, in the second quarter of 2013, compared with a net loss of $1.3 million, or $0.08 per share, in the same period a year ago.

The Company ended the quarter with $7.5 million in cash compared with $8.8 million at the end of the first quarter of 2013 and $7.9 million at the end of fiscal 2012. The Company's backlog at the end of the second quarter was approximately $714,000.

"The second quarter demonstrated the value of our initiatives to improve gross margins and reduce operating expenses as we reduced our net loss by more than 50 percent versus the second quarter a year ago. On a sequential basis, revenues increased nearly $700,000 versus the first quarter of 2013, as we sold three more of our BioArchive System devices versus the prior quarter and recorded revenues from the initial shipment of our AutoXpress ® Platform (AXP) bagsets to Golden Meditech Holdings Limited in China as part of our new product purchase and distribution agreement," said Matthew Plavan, Chief Executive Officer.

"We were also pleased to sign the agreement to divest the ThermoLine product line at the end of the second quarter. We anticipate closing this transaction in the third quarter, which will mark the completion of the disposition of our non-core product lines, ThermoLine and CryoSeal. Together with the $500,000 we received at the end of the second quarter for the ThermoLine product line, these divestitures have generated a total of $3.5 million in cash with $2.5 million of that received in the last six months. In addition, our restructuring and streamlining initiatives have reduced our operating and overhead expenses by more than $2 million annually, serving our goal of creating a stronger organization more focused on our core cord blood and stem cell regenerative medicine businesses," he added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs